четверг, 14 января 2016 г.

a Stay of Litigation Pending Ipr Does Not Provide a Basis For Extending 30-Stay of Fda Anda Approval

a Stay of Litigation Pending Ipr Does Not Provide a Basis For Extending 30-Stay of Fda Anda Approval


On December 11, 2015, the United States District Court for the Southern District of Indiana granted a motion to stay a Hatch-Waxman litigation pending the outcome of inter partes reviews on two of the patents-in-suit in the litigation. See Eli Lilly and Company, et al. vs. Accord Healthcare Inc., et al. , No.



from Biotech News